Eurofins Further Reinforces Its Market Leadership in Environment Testing with the Acquisition of VBM Laboratories in Denmark
March 24 2017 - 5:18AM
Business Wire
Regulatory News:
Eurofins Scientific (Paris:ERF) (EUFI.PA), the global leader in
food and environment testing, announces that it has acquired VBM
Laboratoriet A/S (“VBM”), one of the leading laboratories for
testing for the environment and construction materials sectors in
Denmark.
Founded in 1985, VBM has developed into one of the top three
environment testing laboratories in the country, with a strong
reputation for testing of contaminated soil and building materials
particularly within the construction sector. The company employs 80
staff across its 3 sites, and generated revenues in excess of DKK
45m in 2016.
VBM’s primary competencies and customer segments in environment
testing strongly complement Eurofins’ capabilities in the local
market. The acquisition of VBM should therefore further strengthen,
as well as expand the Group’s leadership in the Danish environment
testing market. As part of the transaction, current VBM leader
Jesper Gamst will remain as managing director of VBM
Laboratories.
Comment from Klaus Melsing Bjørnholdt and Jesper
Gamst, VBM shareholders: “We are proud to have developed VBM
Laboratories to be one of the market leaders in Denmark and we are
convinced that the agreement with Eurofins will safeguard further
positive development for VBM and its team”.
Comment from Dr. Gilles Martin, Eurofins CEO: “The
acquisition of VBM demonstrates our commitment to continually
reinforce our leadership in markets where we are active. The
complementary businesses of VBM and Eurofins also illustrate the
Group’s strategy of expanding our leading operational footprint. We
look forward to supporting VBM in further developing their market
share together with Eurofins, by providing access to the full range
of capabilities of the Group.
For more information, please visit
www.eurofins.com
Notes for the editor:
Eurofins – a global leader in bio-analysis
Eurofins Scientific through its subsidiaries (hereinafter
sometimes “Eurofins” or “the Group”) believes it is the world
leader in food, environment and pharmaceutical products testing and
that it is also one of the global independent market leaders in
certain testing and laboratory services for agroscience, genomics,
discovery pharmacology and for supporting clinical studies. In
addition, Eurofins is one of the key emerging players in specialty
clinical diagnostic testing in Europe and the USA. With over 27,000
staff in 310 laboratories across 39 countries, Eurofins offers a
portfolio of over 130,000 analytical methods for evaluating the
safety, identity, composition, authenticity, origin and purity of
biological substances and products, as well as for innovative
clinical diagnostic. The Group objective is to provide its
customers with high-quality services, accurate results on time and
expert advice by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by
expanding both its technology portfolio and its geographic reach.
Through R&D and acquisitions, the Group draws on the latest
developments in the field of biotechnology and analytical chemistry
to offer its clients unique analytical solutions and the most
comprehensive range of testing methods.
As one of the most innovative and quality oriented international
players in its industry, Eurofins is ideally positioned to support
its clients’ increasingly stringent quality and safety standards
and the expanding demands of regulatory authorities around the
world.
The shares of Eurofins Scientific are listed on the Euronext
Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg
ERF FP).
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgement
of Eurofins Scientific’ management as of the date of this release.
These forward-looking statements are not guarantees for future
performance, and the forward-looking events discussed in this
release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and
estimates. All statements and estimates are made based on the
information available to the Company’s management as of the date of
publication, but no guarantee can be made as to their validity.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170324005225/en/
Investor RelationsEurofins ScientificPhone: +32 2 766
1620E-mail: ir@eurofins.com
Enerplus (NYSE:ERF)
Historical Stock Chart
From Sep 2024 to Oct 2024
Enerplus (NYSE:ERF)
Historical Stock Chart
From Oct 2023 to Oct 2024